University of California, San Francisco, San Francisco, California.
Clin Cancer Res. 2020 Jun 15;26(12):2771-2773. doi: 10.1158/1078-0432.CCR-20-0604. Epub 2020 Apr 7.
It has been demonstrated that, in early breast cancer, there is no survival benefit to additional treatment once a patient has achieved a pathologic complete response (pCR). Together with the well-established prognostic association between pCR and survival, this presents a strong rationale for escalation/deescalation of neoadjuvant treatment based upon response..
已经证实，在早期乳腺癌中，一旦患者达到病理完全缓解（pCR），额外的治疗并不能带来生存获益。加上 pCR 与生存之间已经确立的预后关联，这为基于反应的新辅助治疗的升级/降级提供了强有力的依据。
